Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.

Autores de IIS La Fe

• Fuencisla Ramos Fortea

  Autor

• Eva Barragán González

  Autor

• 

  María Ángeles Tormo Mas

  Autor

• José Vicente Cervera Zamora

  Autor

• Esperanza Such Taboada

  Autor

• Guillermo Sanz Santillana

  Autor

Participantes ajenos a IIS La Fe

• Arenillas L
• Mallo M
• Guinta K
• Lumbreras E
• Larráyoz MJ
• De Paz R
• Abáigar M
• Pedro C
• José Calasanz M
• Díez-Campelo M
• Hernández JM
• Luño E
• Saumell S
• Maciejewski J
• Florensa L
• Solé F

Grupos

• Hematología y Hemoterapia

Abstract

Cytogenetic aberrations identified by metaphase cytogenetics (MC) have diagnostic, prognostic, and therapeutic implications in myelodysplastic syndromes (MDS). However, in some MDS patients MC study is unsuccesful. Single nucleotide polymorphism array (SNP-A) based karyotyping could be helpful in these cases. We performed SNP-A in 62 samples from bone marrow or peripheral blood of primary MDS with an unsuccessful MC study. SNP-A analysis enabled the detection of aberrations in 31 (50%) patients. We used the copy number alteration information to apply the International Prognostic Scoring System (IPSS) and we observed differences in survival between the low/intermediate-1 and intermediate-2/high risk patients. We also saw differences in survival between very low/low/intermediate and the high/very high patients when we applied the revised IPSS (IPSS-R). In conclusion, SNP-A can be used successfully in PB samples and the identification of CNA by SNP-A improve the diagnostic and prognostic evaluation of this group of MDS patients.